ADRB2 and neoplasm: Prostate adenocarcinoma may transdifferentiate via NED into neuroendocrine prostate cancer (NEPC), a more aggressive and advanced tumour, induced by treatments including ADT or other therapies targeting components of the AR signalling pathway such as ADRB2 activation [99].